Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

With the salesforce ramping up and regulatory approval of the 15-day G7 sensor expected this year, we anticipate Dexcom can return to double-digit top and bottom-line growth in 2025. We think the ...

The bottom line also ... with the 15-day G7 CGM could provide a long-term boost. While challenges such as competitive pressures and channel mix shifts remain, DexCom appears well-positioned ...

DexCom specializes in continuous glucose monitoring systems, primarily focusing on individuals managing diabetes. Its innovative CGM systems, like the G6 and the newer G7, offer real-time glucose ...

The bottom line also outpaced the consensus mark ... driven by the expanded availability of G7 and Dexcom ONE+. It launched G7 in Australia and Dexcom ONE+ in France during the third quarter ...